RAJAF.US Cordyceps Sunshine Biotech Holdings Co., Ltd.
- Market cap
- USD 1.02B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is RAJAF.US undervalued?
Graham numberThe Graham number of Cordyceps Sunshine Biotech Holdings Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cordyceps Sunshine Biotech Holdings Co., Ltd. fundamental analysis
No fundamental analysis for Cordyceps Sunshine Biotech Holdings Co., Ltd. yet.
Cordyceps Sunshine Biotech Holdings Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cordyceps Sunshine Biotech Holdings Co., Ltd.
TFA Therapeutics, Inc. develops TFA-01 novel nonsteroidal anti-inflammatory drugs for pet medical care. It offers drugs in the areas of canine osteoarthritis, dermatitis, and feline stomatitis. The company serves customers in Taiwan, Japan, Greater China, and United States. TFA Therapeutics, Inc. was formerly known as Cordyceps Sunshine Biotech Holdings Co., Ltd. and changed its name to TFA Therapeutics, Inc. in July 2026. The company was incorporated in 2020 and is based in…
Full company profileCordyceps Sunshine Biotech Holdings Co., Ltd. financial statements
Cordyceps Sunshine Biotech Holdings Co., Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 53.3K | 883K | 1.25M | 1.25M |
| Gross Profit | 0.00 | 39.6K | 766K | 906K | 761K |
| Operating Income | -119K | -415K | 228K | -184K | -141K |
| EBITDA | - | -391K | 285K | 240K | 68.1K |
| Net Income | -491K | -720K | 752K | -226K | -155K |
| EPS | 0.00 | -0.01 | 0.01 | 0.00 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 3.26M | 2.10M | 3.35M | 4.62M | 4.66M |
| Total Liabilities | 3.54M | 3.06M | 3.50M | 5.00M | 5.19M |
| Shareholders' Equity | -276K | -951K | -152K | -376K | -535K |
| Cash & Short-term Investments | 99.7K | 6.63K | 23.1K | 37.3K | 3.20K |
| Cash Flow | |||||
| Operating Cash Flow | -365K | -321K | 360K | 312K | -35.8K |
| Capital Expenditure | 100K | 475.00 | 319K | 349K | 0.00 |
| Free Cash Flow | -465K | -321K | 40.2K | -37.2K | -35.8K |
| Ratios | |||||
| ROA | -15.0% | -34.2% | 22.4% | -4.9% | -3.3% |
| Net Profit Margin | - | -1,350.9% | 85.2% | -18.1% | -12.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cordyceps Sunshine Biotech Holdings Co., Ltd. dividends
Cordyceps Sunshine Biotech Holdings Co., Ltd. has not paid dividends in the last 5 fiscal years.
Who owns Cordyceps Sunshine Biotech Holdings Co., Ltd.
- Insiders 83.56%
- Institutions 0.00%
- Public & others 16.45%
- Shares outstanding 111M
- Free float 18.3M
Cordyceps Sunshine Biotech Holdings Co., Ltd. company profile
- Company name
- Cordyceps Sunshine Biotech Holdings Co., Ltd.
- Ticker
- RAJAF.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Employees
- 15
- Fiscal year end
- December
- Address
- No. 15, Lane 548, Taipei, Taiwan, 114063
- Phone
- 886 2 2748 9091
- Website
- tfabio.com
About Cordyceps Sunshine Biotech Holdings Co., Ltd.
TFA Therapeutics, Inc. develops TFA-01 novel nonsteroidal anti-inflammatory drugs for pet medical care. It offers drugs in the areas of canine osteoarthritis, dermatitis, and feline stomatitis. The company serves customers in Taiwan, Japan, Greater China, and United States. TFA Therapeutics, Inc. was formerly known as Cordyceps Sunshine Biotech Holdings Co., Ltd. and changed its name to TFA Therapeutics, Inc. in July 2026. The company was incorporated in 2020 and is based in Taipei, Taiwan.
Cordyceps Sunshine Biotech Holdings Co., Ltd. management
1- Mr. Szu Hao HuangCEO, CFO & Director · born 1980